Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunovant (IMVT) Income towards Parent Company (2018 - 2026)

Immunovant filings provide 8 years of Income towards Parent Company readings, the most recent being -$110.6 million for Q4 2025.

  • Quarterly Income towards Parent Company changed 0.44% to -$110.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$464.2 million through Dec 2025, down 21.29% year-over-year, with the annual reading at -$413.8 million for FY2025, 59.58% down from the prior year.
  • Income towards Parent Company hit -$110.6 million in Q4 2025 for Immunovant, up from -$126.5 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at -$28.2 million in Q1 2021 and bottomed at -$126.5 million in Q3 2025.
  • Average Income towards Parent Company over 5 years is -$71.3 million, with a median of -$61.3 million recorded in 2022.
  • The largest annual shift saw Income towards Parent Company grew 18.68% in 2023 before it tumbled 116.11% in 2024.
  • Immunovant's Income towards Parent Company stood at -$41.4 million in 2021, then plummeted by 52.78% to -$63.2 million in 2022, then rose by 18.68% to -$51.4 million in 2023, then tumbled by 116.11% to -$111.1 million in 2024, then rose by 0.44% to -$110.6 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Income towards Parent Company are -$110.6 million (Q4 2025), -$126.5 million (Q3 2025), and -$120.6 million (Q2 2025).